Would you like to know if you’ve had COVID-19?
The BioDiagnostics BioCard™ was developed in direct response to the COVID-19 pandemic, with research beginning in February 2020 in the UK. The BioCard™ utilises the company’s 40 years’ experience in antibody testing and its extensive in vitro diagnostics expertise. The BioCard™ is CE marked and available for delivery throughout the UK and Europe immediately, and the USA imminently.
Physical adaptations from the established QuickCard™ technology, combined with specific changes to the Biochemistry of the device, have resulted in a robust, accurate and ultra-rapid IgG antibody test indicative of a COVID-19 specific immune response.
A positive result demonstrates the presence of specific antibodies to protect against COVID-19, almost certainly inferring past infection.
These specific antibodies are the same ones it is anticipated will be elicited by vaccines currently in development, which aim which provide immunity to COVID-19 infections. If you have a positive result, it very strongly suggests your body has already made them, naturally.